Sitagliptin (Januvia)

DPP-4 (dipeptidyl peptidase) 4 inhibitor.

Dipeptidyl peptidase inhibitor that prevents the proteolysis of endogenous GLP-1

Inhibits the dipeptidyl peptidase4 (DPP-4) activity of CD 26, a highly multi functional cell surface glycoprotein expressed in many tissues throughout the body.

Enhances physiologic glucose control by enhancing incretins.

It inhibits DPP-4 mediated degradation of hormones that stimulate insulin secretion.

Delivers 24 hour glycemic control without weight gain or increased of hypoglycemia.

Indicated as an adjunct to diet and exercise for type 2 diabetes.

Associated with pancreatitis.

Dose adjustments needed for renal insufficiency.

100 mg tablets once daily.

May be associated with pancreatitis acting through the GLP-1 pathway.

Associated with a six times the increase in reported cases of pancreatitis, a 2.7 times higher rate of pancreatic cancer

An oral medication which is taken once a day, either alone with diet and exercise, or in combination with other oral diabetes medications.

Mimics the action of incretin hormones which help the body make more insulin.

Also slow the rate of digestion so that glucose enters the blood more slowly.

People on incretin mimetics feel full longer, which reduces food intake, which helps some people lose weight while on the medication.

Sitagliptin added to standard immunosuppressive regimen of tacrolimus and sirolimus resulted in a low incidence of acute graph versus host disease after hematopoetic stem cell transplant from HLA matched related or unrelated donors.

It inhibits enzymatic degradation of growth factors the production that promote the production of blood cells after HSCT with umbilical cord blood cells.




Leave a Reply

Your email address will not be published. Required fields are marked *